AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11071086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteria eradicated
Number of subjects: 20
Study 11071086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteria persisted
Number of subjects: 20
Study 8716525 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 50
Study 8716525 — intervention group
Group type: COMPARATOR
Intervention: Standard positioning
Number of subjects: 50
Study 1484383 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched strategy (high CCSI score)
Number of subjects: 0
Study 1484383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatched strategy (low CCSI score)
Number of subjects: 0
Study 1484383 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of strategies
Number of subjects: 0
Study 3883232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 20
Study 3883232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31758589 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkali-modified implants
Number of subjects: 14
Study 31758589 — intervention group
Group type: COMPARATOR
Intervention: Sandblasted implants
Number of subjects: 14
Study 30663262 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO International Reference Reagent (89/666)
Number of subjects: 52
Study 30663262 — intervention group
Group type: COMPARATOR
Intervention: Whole blood EQA specimen
Number of subjects: 52
Study 28399035 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% tacrolimus eye drops
Number of subjects: 40
Study 28399035 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha‐2b (1,000,000 units/cc) eye drops
Number of subjects: 40
Study 25418873 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing in urine
Number of subjects: 216
Study 23860674 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks above-elbow cast (AEC)
Number of subjects: 47
Study 23860674 — intervention group
Group type: COMPARATOR
Intervention: 3 weeks above-elbow cast (AEC) followed by 3 weeks below-elbow cast (BEC)
Number of subjects: 47
Study 23860674 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks AEC
Number of subjects: 47
Study 23860674 — intervention group
Group type: COMPARATOR
Intervention: 3 weeks AEC followed by 3 weeks BEC
Number of subjects: 47
Study 21887713 — intervention group
Group type: EXPERIMENTAL
Intervention: Soldier-expressive writing
Number of subjects: 102
Study 21887713 — intervention group
Group type: COMPARATOR
Intervention: Soldier-control writing
Number of subjects: 102
Study 21887713 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse-expressive writing
Number of subjects: 102
Study 21887713 — intervention group
Group type: COMPARATOR
Intervention: Spouse-control writing
Number of subjects: 102
Study 18594971 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline, co-amoxiclav, omeprazole (Group A)
Number of subjects: 189
Study 18594971 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, omeprazole, furazolidone, bismuth (Group B)
Number of subjects: 189
Study 18594971 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, clarithromycin, omeprazole (Group C)
Number of subjects: 189
Study 16439432 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (4 mg kg(‐1)) + Antioxidants (1 g ascorbic acid i.v. and 200 mg alpha‐tocopherol p.o.)
Number of subjects: 16
Study 16439432 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide (4 mg kg(‐1)) + Placebo
Number of subjects: 16
Study 12890401 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg every 12 hours)
Number of subjects: 50
Study 12890401 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (adjusted doses)
Number of subjects: 50
Study 11208394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine treatment for 8 weeks, diet restriction, and regular exercise
Number of subjects: 55
Study 11208394 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks, no behavioral treatment
Number of subjects: 55
Study 11208394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine treatment for 8 weeks followed by 42 months of intervention
Number of subjects: 55
Study 11208394 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks followed by 42 months of non-intervention
Number of subjects: 55
Study 9235656 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injections of glucocorticosteroids
Number of subjects: 69
Study 9235656 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 69
Study 9235656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone phonophoresis
Number of subjects: 69
Study 9235656 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with sinusoidal modulated currents (SMC)
Number of subjects: 69
Study 9235656 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser radiation
Number of subjects: 69
Study 9235656 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids injections
Number of subjects: 69
Study 1389662 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (intraarterial injection)
Number of subjects: 39
Study 1389662 — intervention group
Group type: EXPERIMENTAL
Intervention: ioxaglate (intraarterial injection)
Number of subjects: 39
Study 1389662 — intervention group
Group type: EXPERIMENTAL
Intervention: ioxaglate (intravenous injection)
Number of subjects: 39
Study 1389662 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (intravenous injection)
Number of subjects: 39
Study 4048081 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-motivation program with biweekly payroll deductions contingent on meeting self-selected weight-loss goals
Number of subjects: 36
Study 4048081 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 36
Study 30044484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse care manager (NCM) strategies during patient interactions
Number of subjects: 41
Study 28482864 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-operative physical activity with moderate aerobic activity and inspiratory muscle training (IMT)
Number of subjects: 640
Study 28482864 — intervention group
Group type: COMPARATOR
Intervention: Standard care (normal daily exercise routine)
Number of subjects: 640
Study 26469232 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical eye (SE)
Number of subjects: 10
Study 24016496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1133
Study 24016496 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1133
Study 21415660 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib (nonsteroidal anti-inflammatory)
Number of subjects: 50
Study 21415660 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (corticosteroid anti-inflammatory)
Number of subjects: 50
Study 21415660 — intervention group
Group type: COMPARATOR
Intervention: Both groups (etoricoxib and dexamethasone)
Number of subjects: 50
Study 18317068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab 250 mg/m(2) weekly IV and gefitinib 250 mg/d PO
Number of subjects: 13
Study 16570217 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific HIV prevention intervention (Project FIO)
Number of subjects: 180
Study 12808176 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (mean dose of 0.68 mg/kg)
Number of subjects: 25
Study 12808176 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (mean bolus of 42.1 IU/kg and continuous infusion of 57.8 IU/kg)
Number of subjects: 25
Study 12808176 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 10475286 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 72
Study 10475286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8590960 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐DAMME 250 micrograms IV as a bolus at time 0'
Number of subjects: 6
Study 8590960 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH 2 IU as an IV bolus at time -180'
Number of subjects: 6
Study 8590960 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐DAMME preceded by hGH
Number of subjects: 6
Study 8590960 — intervention group
Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 6
Study 1706666 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 41
Study 1706666 — intervention group
Group type: COMPARATOR
Intervention: low-dose epirubicin
Number of subjects: 41
Study 1706666 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin after failure of estramustine phosphate
Number of subjects: 41
Study 7042201 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 36
Study 7042201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 36
Study 7042201 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 7042201 — intervention group
Group type: EXPERIMENTAL
Intervention: Unable to tolerate antacids
Number of subjects: 36
Study 7042201 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (antacids or cimetidine)
Number of subjects: 36
Study 7042201 — intervention group
Group type: COMPARATOR
Intervention: No medications
Number of subjects: 36
Study 31788783 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous VBAC
Number of subjects: 38686
Study 31788783 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous cesarean section for non-cephalic presentation
Number of subjects: 38686
Study 31788783 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous cesarean section due to dystocia
Number of subjects: 38686
Study 31788783 — intervention group
Group type: EXPERIMENTAL
Intervention: <18 months since last cesarean section
Number of subjects: 38686
Study 31788783 — intervention group
Group type: EXPERIMENTAL
Intervention: Model prediction using ROC curve
Number of subjects: 38686
Study 30834689 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulation with di- and tripeptides
Number of subjects: 60
Study 30834689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation based on hydrolyzed collagen
Number of subjects: 60
Study 30834689 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 60
Study 30059671 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-0976 20 mg
Number of subjects: 126
Study 30059671 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-0976 5 mg
Number of subjects: 126
Study 30059671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 30059671 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-0976
Number of subjects: 126
Study 26817934 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 463
Study 26817934 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Blocks (BB)
Number of subjects: 463
Study 26817934 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 463
Study 25181386 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3307
Study 21934157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored activity pacing instruction
Number of subjects: 32
Study 21934157 — intervention group
Group type: COMPARATOR
Intervention: General activity pacing instruction
Number of subjects: 32
Study 20855168 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Enhanced Behavioral Self-Management program (WEB-SM)
Number of subjects: 118
Study 20855168 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study 17667837 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat dressings
Number of subjects: 20
Study 17667837 — intervention group
Group type: COMPARATOR
Intervention: 5% sulfamylon-soaked burn wound dressings
Number of subjects: 20
Study 16135475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57
Study 16135475 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 57
Study 11981362 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily SQV-SGC/RTV (1600/100 mg)
Number of subjects: 69
Study 10420097 — intervention group
Group type: COMPARATOR
Intervention: Group A (greater MMN amplitudes)
Number of subjects: 0
Study 10420097 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (lower MMN amplitudes)
Number of subjects: 0
Study 7551972 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 7551972 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 7551972 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 0
Study 2043500 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAP (dexamethasone/high‐dose cytarabine/cisplatin) for two courses at 3‐ to 4‐week intervals
Number of subjects: 50
Study 2043500 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT (autologous bone marrow transplantation) following DHAP
Number of subjects: 50
Study 2043500 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival for patients undergoing transplantation
Number of subjects: 50
Study 2043500 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 50
Study 6118769 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing after birth
Number of subjects: 0
Study 6118769 — intervention group
Group type: COMPARATOR
Intervention: Bathing after birth
Number of subjects: 0
Study 31096925 — intervention group
Group type: COMPARATOR
Intervention: Traditional triage algorithm
Number of subjects: 42542
Study 31096925 — intervention group
Group type: COMPARATOR
Intervention: Triage algorithm with clinical assessment and vital signs
Number of subjects: 42542
Study 31096925 — intervention group
Group type: COMPARATOR
Intervention: Triage algorithm with routine biomarkers
Number of subjects: 42542
Study 31096925 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR biomarker
Number of subjects: 42542
Study 28697991 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 400 mg before surgery
Number of subjects: 90
Study 28697991 — intervention group
Group type: COMPARATOR
Intervention: Control (no carbamazepine)
Number of subjects: 90
Study 28697991 — intervention group
Group type: EXPERIMENTAL
Intervention: Addicted patients (no treatment)
Number of subjects: 90
Study 26244705 — intervention group
Group type: EXPERIMENTAL
Intervention: Block randomization
Number of subjects: 0
Study 26244705 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified randomization
Number of subjects: 0
Study 26244705 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimization
Number of subjects: 0
Study 26244705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hierarchical randomization
Number of subjects: 0
Study 23586805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-construal mindset (considering learning from proximity)
Number of subjects: 0
Study 23586805 — intervention group
Group type: EXPERIMENTAL
Intervention: High-construal mindset (considering learning from temporal distance)
Number of subjects: 0
Study 21592946 — intervention group
Group type: EXPERIMENTAL
Intervention: Active use of stereotypes to make predictions met with reward and punishment
Number of subjects: 320
Study 21592946 — intervention group
Group type: COMPARATOR
Intervention: Noise-based accounts
Number of subjects: 320
Study 21592946 — intervention group
Group type: COMPARATOR
Intervention: Discrepancy-reducing feedback learning
Number of subjects: 320
Study 21592946 — intervention group
Group type: COMPARATOR
Intervention: Simulations
Number of subjects: 320
Study 19700669 — intervention group
Group type: EXPERIMENTAL
Intervention: Northwestern Anagram Test (NAT)
Number of subjects: 16
Study 19700669 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 18193497 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 115
Study 18193497 — intervention group
Group type: COMPARATOR
Intervention: Self-administered therapy (SAT)
Number of subjects: 115
Study 12914622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing + Shock
Number of subjects: 11
Study 12914622 — intervention group
Group type: COMPARATOR
Intervention: Shock Only
Number of subjects: 11
Study 10950231 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg oral insulin daily
Number of subjects: 131
Study 10950231 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg oral insulin daily
Number of subjects: 131
Study 10950231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 9210279 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminist-cognitive-behavioral treatment
Number of subjects: 218
Study 9210279 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-psychodynamic treatment
Number of subjects: 218
Study 1422321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 1422321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/day of conjugated estrogens
Number of subjects: 133
Study 1422321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg/day of conjugated estrogens
Number of subjects: 133
Study 1422321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/day of conjugated estrogens plus 600 mg/day of ipriflavone
Number of subjects: 133
Study 1422321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg/day of conjugated estrogens plus 600 mg/day of ipriflavone
Number of subjects: 133
Study 4045362 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic sphygmomanometer
Number of subjects: 14
Study 4045362 — intervention group
Group type: COMPARATOR
Intervention: Hawksley random zero instrument
Number of subjects: 14
Study 4045362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff position for the automatic instrument
Number of subjects: 14
Study 3435694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release verapamil
Number of subjects: 10
Study 3435694 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation of verapamil
Number of subjects: 10
Study 3435694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 10
Study 31613320 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose (HD) group took 4 mg 17ß‐estradiol/d orally.
Number of subjects: 20
Study 31613320 — intervention group
Group type: COMPARATOR
Intervention: Lower dose (LD) group took 2 mg 17ß‐estradiol/d orally and placebo.
Number of subjects: 20
Study 29675680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus capecitabine
Number of subjects: 149
Study 29675680 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus capecitabine
Number of subjects: 149
Study 29200984 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (CHO)
Number of subjects: 8
Study 29200984 — intervention group
Group type: COMPARATOR
Intervention: Water (CON)
Number of subjects: 8
Study 26034927 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid (ALA) 600 mg/day
Number of subjects: 60
Study 26034927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24103510 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and copper syrup with zinc (10 mg of iron, 0.5 mg of copper, and 10 mg of zinc)
Number of subjects: 251
Study 24103510 — intervention group
Group type: COMPARATOR
Intervention: Iron and copper syrup without zinc (10 mg of iron and 0.5 mg of copper)
Number of subjects: 251
Study 20947155 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐SE etch
Number of subjects: 29
Study 20947155 — intervention group
Group type: COMPARATOR
Intervention: C‐SE non‐etch
Number of subjects: 29
Study 18230263 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg/kg
Number of subjects: 90
Study 18230263 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg
Number of subjects: 90
Study 18230263 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 90
Study 16340688 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP model of care
Number of subjects: 0
Study 16340688 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study 14566254 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated oxygenator (UnModified Surface)
Number of subjects: 71
Study 14566254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenator coated with BioPassive Surface
Number of subjects: 71
Study 14566254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenator coated with BioActive Surface
Number of subjects: 71
Study 14566254 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 71
Study 11128679 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid and aspirin 325 mg taken concomitantly
Number of subjects: 11
Study 11128679 — intervention group
Group type: COMPARATOR
Intervention: Probenecid alone
Number of subjects: 11
Study 11128679 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid followed by aspirin 325 mg at 6 hours
Number of subjects: 11
Study 8981334 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesclim 50
Number of subjects: 283
Study 8981334 — intervention group
Group type: COMPARATOR
Intervention: Estraderm TTS 50
Number of subjects: 283
Study 1478369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (continuous subcutaneous insulin infusion)
Number of subjects: 27
Study 1478369 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 27
Study 6487749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen capsules (200 mg)
Number of subjects: 9
Study 6487749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release pellets (200 mg)
Number of subjects: 9
Study 6487749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release pellets (200 mg) once every 24 h
Number of subjects: 9
Study 6487749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen capsules (50 mg) every 6 h
Number of subjects: 9
Study 30323322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol (5-day course)
Number of subjects: 55
Study 30323322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 28738672 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings group
Number of subjects: 18